The dopamine D3 receptor (DRD3) gene and risk of schizophrenia: Case-control studies and an updated meta-analysis

Ayako Nunokawa, Yuichiro Watanabe, Naoshi Kaneko, Takuro Sugai, Saori Yazaki, Tadao Arinami, Hiroshi Ujike, Toshiya Inada, Nakao Iwata, Hiroshi Kunugi, Tsukasa Sasaki, Masanari Itokawa, Norio Ozaki, Ryota Hashimoto, Toshiyuki Someya

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.

Original languageEnglish
Pages (from-to)61-67
Number of pages7
JournalSchizophrenia Research
Volume116
Issue number1
DOIs
Publication statusPublished - 01-01-2010

Fingerprint

Dopamine D3 Receptors
Single Nucleotide Polymorphism
Meta-Analysis
Case-Control Studies
Schizophrenia
Haplotypes
Genes
Sample Size
Population
HapMap Project
Databases

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Nunokawa, Ayako ; Watanabe, Yuichiro ; Kaneko, Naoshi ; Sugai, Takuro ; Yazaki, Saori ; Arinami, Tadao ; Ujike, Hiroshi ; Inada, Toshiya ; Iwata, Nakao ; Kunugi, Hiroshi ; Sasaki, Tsukasa ; Itokawa, Masanari ; Ozaki, Norio ; Hashimoto, Ryota ; Someya, Toshiyuki. / The dopamine D3 receptor (DRD3) gene and risk of schizophrenia : Case-control studies and an updated meta-analysis. In: Schizophrenia Research. 2010 ; Vol. 116, No. 1. pp. 61-67.
@article{54745804e9804fa19e8eae9af395cc99,
title = "The dopamine D3 receptor (DRD3) gene and risk of schizophrenia: Case-control studies and an updated meta-analysis",
abstract = "The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.",
author = "Ayako Nunokawa and Yuichiro Watanabe and Naoshi Kaneko and Takuro Sugai and Saori Yazaki and Tadao Arinami and Hiroshi Ujike and Toshiya Inada and Nakao Iwata and Hiroshi Kunugi and Tsukasa Sasaki and Masanari Itokawa and Norio Ozaki and Ryota Hashimoto and Toshiyuki Someya",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.schres.2009.10.016",
language = "English",
volume = "116",
pages = "61--67",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1",

}

Nunokawa, A, Watanabe, Y, Kaneko, N, Sugai, T, Yazaki, S, Arinami, T, Ujike, H, Inada, T, Iwata, N, Kunugi, H, Sasaki, T, Itokawa, M, Ozaki, N, Hashimoto, R & Someya, T 2010, 'The dopamine D3 receptor (DRD3) gene and risk of schizophrenia: Case-control studies and an updated meta-analysis', Schizophrenia Research, vol. 116, no. 1, pp. 61-67. https://doi.org/10.1016/j.schres.2009.10.016

The dopamine D3 receptor (DRD3) gene and risk of schizophrenia : Case-control studies and an updated meta-analysis. / Nunokawa, Ayako; Watanabe, Yuichiro; Kaneko, Naoshi; Sugai, Takuro; Yazaki, Saori; Arinami, Tadao; Ujike, Hiroshi; Inada, Toshiya; Iwata, Nakao; Kunugi, Hiroshi; Sasaki, Tsukasa; Itokawa, Masanari; Ozaki, Norio; Hashimoto, Ryota; Someya, Toshiyuki.

In: Schizophrenia Research, Vol. 116, No. 1, 01.01.2010, p. 61-67.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The dopamine D3 receptor (DRD3) gene and risk of schizophrenia

T2 - Case-control studies and an updated meta-analysis

AU - Nunokawa, Ayako

AU - Watanabe, Yuichiro

AU - Kaneko, Naoshi

AU - Sugai, Takuro

AU - Yazaki, Saori

AU - Arinami, Tadao

AU - Ujike, Hiroshi

AU - Inada, Toshiya

AU - Iwata, Nakao

AU - Kunugi, Hiroshi

AU - Sasaki, Tsukasa

AU - Itokawa, Masanari

AU - Ozaki, Norio

AU - Hashimoto, Ryota

AU - Someya, Toshiyuki

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.

AB - The dopamine D3 receptor (DRD3) has been suggested to be involved in the pathophysiology of schizophrenia. DRD3 has been tested for an association with schizophrenia, but with conflicting results. A recent meta-analysis suggested that the haplotype T-T-T-G for the SNPs rs7631540-rs1486012-rs2134655-rs963468 may confer protection against schizophrenia. However, almost all previous studies of the association between DRD3 and schizophrenia have been performed using a relatively small sample size and a limited number of markers. To assess whether DRD3 is implicated in vulnerability to schizophrenia, we conducted case-control association studies and performed an updated meta-analysis. In the first population (595 patients and 598 controls), we examined 16 genotyped single nucleotide polymorphisms (SNPs), including tagging SNPs selected from the HapMap database and SNPs detected through resequencing, as well as 58 imputed SNPs that are not directly genotyped. To confirm the results obtained, we genotyped the SNPs rs7631540-rs1486012-rs2134655-rs963468 in a second, independent population (2126 patients and 2228 controls). We also performed an updated meta-analysis of the haplotype, combining the results obtained in five populations, with a total sample size of 7551. No supportive evidence was obtained for an association between DRD3 and schizophrenia in our Japanese subjects. Our updated meta-analysis also failed to confirm the existence of a protective haplotype. To draw a definitive conclusion, further studies using larger samples and sufficient markers should be carried out in various ethnic populations.

UR - http://www.scopus.com/inward/record.url?scp=71549168918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71549168918&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2009.10.016

DO - 10.1016/j.schres.2009.10.016

M3 - Article

C2 - 19897343

AN - SCOPUS:71549168918

VL - 116

SP - 61

EP - 67

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1

ER -